The Brookings Institute announced that it will be hosting a heated debate on Thursday, April 14 over marijuana’s current Schedule 1 status within the Controlled Substance Act.
Advocates for medicinal cannabis have been in a long winded battle with our federal government over the Controlled Substance Act, which is incredibly outdated and could use some 2016 revisions. The Brookings Institute is scheduled to host an informative debate between Oregon’s Democratic Rep. Earl Blumenauer and Dr. Bertha K. Madras, a Professor of Psychobiology at Harvard’s Medical School. The matter at hand? Cannabis being considered an illegal and dangerous “drug”. The main question going to be discussed? “What are the potential pros & cons and costs & benefits of the federal government reclassifying marijuana as a less dangerous drug?”. Focusing on whether or not the plant has any “currently accepted medical use”, the debate will scrutinize the critical verbiage within the legal definition of a Schedule I substance as defined by the CSA. Prepare yourselves for a lively discussion on the consequences of potentially reclassifying marijuana. So far 23 states plus the District of Columbia have disregarded the federal government and legalized medicinal cannabis, allowing their citizens to legally access the plant’s active cannabinoids as treatment for a vast list of serious ailments. Because of the CSA, the issue of cannabis plants as legal forms of medicine has promoted bigger and bigger rifts to grow between states and the government, encouraging secrecy and lies, and “illegal activity” based on the U.S. drug policy. This causes concerns for doctors, who want to help their patients; patients, who are sick and seeking alternative forms of help and treatment; and dispensaries, who wants to help and provide for both patients and doctors. Time will tell, tune in April 14th to catch the action and help Make America Progress Again!